8th SCIENTIFIC SESSIONS CORPORATE SYMPOSIA AT-A-GlANCE

FRIDAY, JUNE 22, 2018:

6:30 p.m.-9:00 p.m.
The Nexus of NASH and Type 2 Diabetes Mellitus: The Emerging Role of the Diabetologist
Jointly provided by Postgraduate Institute for Medicine (PIM) and Integritas Communications
Supported by an educational grant from Gilead Sciences, Inc.

(6:30 p.m.–7:00 p.m.–Registration and Dinner/7:00 p.m.–9:00 p.m.–Educational Activity)

This Interactive Exchange™ symposium examines the overlapping type 2 diabetes and fatty liver disease epidemics, focusing on diabetologists’ essential roles in identifying and managing cases of nonalcoholic steatohepatitis (NASH). Key topics include pathophysiologic links among obesity, diabetes, and NASH; updated diagnostic guidelines; and evidence for current and emerging NASH therapies.

Location: Hyatt Regency Orlando, Plaza International Ballroom H-K
Contact: Katie Anderton/E-mail: kanderton@integritasgrp.com

6:30 p.m.–9:10 p.m.
The Foundational Role of Physiologic, Long-Acting Basal Insulin—Optimizing the Safety-Efficacy Equation in Vulnerable Patients with Type 2 Diabetes
Supported by CMEducation Resources
Supported by an educational grant from Sanofi Diabetes

(6:30 p.m.–7:00 p.m.–Dinner/7:00 p.m.–9:10 p.m.–Program)

This program will focus on the role, indications, guidelines, and evidence supporting optimal approaches to early use, dosing, switching to, and intensification of physiologic, long-acting basal insulin therapy for type 2 diabetes, and when appropriate, in combination with other therapies; and, provide an individualized and patient needs-specific “evidence-based roadmap,” consistent with ADA/EASD position.

Location: Hyatt Regency Orlando, Regency Ballroom O-R
Contact: Milo Falcon/E-mail: milo.falcon@pharmatecture.net

6:30 p.m.–9:15 p.m.
The Mechanistic and Therapeutic Rationale for Dual SGLT1/2 Inhibition in Adults with Type 1 Diabetes
Supported by CMEducation Resources
Supported by an educational grant from Sanofi Diabetes

(6:30 p.m.–7:00 p.m.–Dinner/7:00 p.m.–9:15 p.m.–Program)

This CME activity will focus on the role, indications, guidelines, and evidence supporting optimal approaches for improving comprehensive glycemic management, HbA1c target goal attainment, safety,
and metabolic optimizing by using agents with mechanistic complementarity with insulin, including those therapies acting through dual SGLT1/2 inhibition, in adults with type 1 diabetes mellitus.

**Location:** Hyatt Regency Orlando, Regency Ballroom S-V  
**Contact:** Milo Falcon/E-mail: milo.falcon@pharmatecture.net

**6:30 p.m.-9:30 p.m.**  
**Los Avances más Recientes en el Manejo de la Diabetes Tipo 2: Un Enfoque más Preciso**  
**Jointly sponsored by** The University of Texas Southwestern Medical Center and Worldwide Initiative for Diabetes Education  
**Supported by an unrestricted educational grant from** Novo Nordisk A/S

(6:30 p.m.–6:45 p.m.–Registration and Buffet Dinner/6:45 p.m.–9:30 p.m.–Educational Program)

La prevalencia global de la diabetes tipo 2 ha alcanzado proporciones epidémicas, exponiendo a un gran porcentaje de la población Latina/Hispana a serias complicaciones de riesgo de vida. La iniciación a tiempo y la intensificación de tratamientos basados en guias terapeuticas pueden mejorar el control glucémico y demorar la prevención de problemas de salud, incluyendo complicaciones cardiovasculares. Este simposio proveerá a los participantes con avances recientes y enfocados sobre el mejor manejo del tratamiento de la diabetes tipo 2.

**Location:** Hyatt Regency Orlando, Plaza International Ballroom D-G  
**Contacts:** Mark Vinciguerra/E-mail: mark.vinciguerra@utsouthwestern.edu  
Jane Savio/E-mail: jane.savio@worldwidediabetes.org

**SATURDAY, JUNE 23, 2018:**

**5:30 a.m.-7:45 a.m.**  
**Continuous Glucose Monitoring Category Update: Clinical Outcomes, New Technologies, and Therapeutic Dosing**  
**Sponsored by** CogniMed  
**Supported by an educational grant from** Dexcom

- Outcomes from the Ihart, HypoDE, DiaMonD, GOLD, Impact, and Replace Study  
- Review of new near term commercial continuous glucose monitoring systems  
- Discuss how to guide patients to dose continuous glucose monitoring in real time

**Location:** Hyatt Regency Orlando, Regency Ballroom O-R  
**Contact:** Jeffrey Rosenberg/E-mail: info@cgmeducation.net

**5:30 a.m.-7:45 a.m.**  
**Clinician Update: New Options and Strategies for Cardiovascular Risk Reduction in Diabetes**  
**Sponsored by** Medtelligence, LLC  
**Supported by an educational grant from** Amarin Pharma Inc.

Updated 5/29/18
This CME program will provide attendees with recent advances in our understanding of the complex interrelationship of cardiovascular disease and type 2 diabetes. The multidisciplinary faculty and symposium participants will work through complex issues that challenge health care providers in caring for patients who often have elevated atherogenic cholesterol and triglycerides, many (or most) of whom have been sub-optimally managed.

**Location:** Hyatt Regency Orlando, Plaza International Ballroom D-G  
**Contact:** Milly Marte/E-mail: mmarte@medtelligence.net

**6:15 p.m.-9:15 p.m.**  
**Multi-Mechanistic, Insulin-Based Approaches for Achieving HbA1c/PPG Targets and Optimizing Safety in Challenging Patients with Type 2 Diabetes**  
**Sponsored by CMEducation Resources**  
**Supported by an educational grant from Sanofi Diabetes**

(6:15 p.m.–6:45 p.m.–Dinner/6:45 p.m.–9:15 p.m.–Program)

This CME activity will focus on the role, indications, guidelines, and evidence supporting “multi-mechanistic” approaches to early use, conversion to, and titration of combination insulin therapy and fixed ratio GLP-combinations; as well as the use of insulin-based formulations in fixed-ratio combination with GLP-1 receptor agonists to optimize metabolic and compliance end points.

**Location:** Hyatt Regency Orlando, Regency Ballroom O-R  
**Contact:** Milo Falcon/E-mail: milo.falcon@pharmatecture.net

**6:15 p.m.-9:15 p.m.**  
**The Landmark Evidence and Clinical Rationale for PCSK9 Inhibition in the Diabetic Patient**  
**Sponsored by CMEducation Resources**  
**Supported by an educational grant from Sanofi and Regeneron**

(6:15 p.m.–6:45 p.m.–Dinner/6:45 p.m.–9:15 p.m.–Program)

This CME activity will focus on landmark clinical cardiovascular outcomes trials, mechanisms of atherosclerotic heart disease, new ACC/ECDP Task Force Guidelines for non-statin-based LDL reduction, novel LDL targets and therapies, and new translational dimensions of applying new cardiovascular outcome data in PCSK9-mediated LDL reduction to the diabetic population.

**Location:** Hyatt Regency Orlando, Regency Ballroom S-V  
**Contact:** Milo Falcon/E-mail: milo.falcon@pharmatecture.net

Updated 5/29/18
Innovations in Diabetic Wound Healing

*Sponsored by* Healogics  
*Supported by an educational grant from* Healogics and Oreganogenesis

In this session, leading experts in wound care will present information on identification, treatment, and healing of diabetic foot ulcers. Join us for a discussion around innovations in wound healing therapies, including standards of care and the use of advanced therapies.

**Location:** Hyatt Regency Orlando, Plaza International Ballroom D-G  
**Contact:** Hanna Gordon/E-mail: hanna.gordon@healogics.com

**6:15 p.m.-9:15 p.m.**  
**Free Style Libre Flash Continuous Glucose Monitoring System: Clinical, Real-World, and Patient Perspectives**  
*Sponsored by* Abbott Diabetes Care  
*Supported by an educational grant from* Abbott Diabetes Care

Panel Discussion:  
Chair of the Symposium: Dr. Bernard Zinman; Use of Flash Continuous Glucose Monitoring and the Ambulatory Glucose Profile in Clinical Practice: Dr. Irl Hirsch; SELFY & IMPACT: Improved Clinical Outcomes in Teens and Young Adults: Dr. Kurt Midyett; Insights from Real World Use of Flash Continuous Glucose Monitoring: Dr. Ramzi Ajjan; Patient Perspectives on Flash Continuous Glucose Monitoring: Kelly Close.

**Location:** Hyatt Regency Orlando, Plaza International Ballroom H-K  
**Contact:** Katherine Bowen/E-mail: katherine.bowen@abbott.com

**SUNDAY, JUNE 24, 2018:**

**5:30 a.m.-7:45 a.m.**  
**Recognizing the Risk: Addressing and Improving Cardiovascular Outcomes in Diabetic Kidney Disease**  
*Sponsored by* Med-IQ  
*Supported by an educational grant from* Bayer Health Care Pharmaceuticals, Inc.

The proposed accredited symposium will address the current research on cardiorenal pathophysiology among those with underlying diabetes as well as associated risk factors and investigational treatment strategies for patients with DKD. The symposium will be sponsored and accredited for 2.0 AMA PRA category 1 credits™, by Med-IQ.

**Location:** Hyatt Regency Orlando, Regency Ballroom O-R  
**Contact:** Whitney Stevens/E-mail: wstevens@med-iq.com

**6:45 p.m.-8:45 p.m.**

Updated 5/29/18
Reducing Cardiovascular Risk in Type 2 Diabetes: What I Do and Why  
Sponsored by Clinical Care Options, LLC  
Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC

(6:45 p.m.–7:15 p.m.–Registration and Dinner/7:15 p.m.–8:45 p.m.–Program)

In this highly interactive program, a panel of expert faculty members will walk you through their individual approaches to selecting appropriate type 2 diabetes mellitus therapy based on clinical trial results and real-world evidence evaluating the impact of therapies on cardiovascular risk.

Location: Hyatt Regency Orlando, Regency Ballroom O-R  
Contact: Amy Goldman/E-mail: agoldman@clinicaloptions.com

6:45 p.m.–8:45 p.m.  
Multifaceted Approaches to Treating Type 2 Diabetes: Individualization Is Key  
Provided by Vindico Medical Education  
Supported by an educational grant from Merck & Co., Inc.

(6:45 p.m.–7:15 p.m.–Registration and Dinner/7:15 p.m.–8:45 p.m.–CME-Certified Activity)

This educational activity will feature expert faculty discussing the effective use of therapeutic strategies in redefining the need to individualize treatment with a patient-first approach and assessing new as well as emerging clinical evidence to improve glycemic control, reducing cardiovascular risk.

Location: Hyatt Regency Orlando, Regency Ballroom S-V  
Contact: Kristin Riday/E-mail: kriday@vindicomeded.com

6:45 p.m.–9:15 p.m.  
Pointed Discussions: Clinical Conversations About Reducing Cardiovascular Risks in Patients with Type 2 Diabetes Mellitus Using Newer Options in Injectable Antihyperglycemic Therapy  
Sponsored by Institute for Medical and Nursing Education  
Supported by an educational grant from Novo Nordisk

(6:45 p.m.–7:15 p.m.–Registration and Dinner/7:15 p.m.–9:15 p.m.–Program)

This CME/CE certified 2-hour dinner program will be implemented using an interactive, video driven, case-based format. Expert faculty will briefly present key educational points, discuss clinically relevant cases, and address participants’ questions regarding the benefits, limitations, and practical aspects of new and existing options in injectable therapy for the management of type 2 diabetes mellitus.

Location: Hyatt Regency Orlando, Plaza International Ballroom H-K  
Contact: Amy Carbonara/E-mail: amy.carbonara@imne.com

6:45 p.m.–9:45 p.m.
The Right Recipe for Achieving Postprandial Glucose Control: To Inhale or Inject?

**Sponsored by Medscape**

**Supported by an educational grant from MannKind Corporation**

This live, interactive symposium will guide participants through a comprehensive diabetes management, including a detailed look at how inhaled insulin can be used to improve patient outcomes. The “diabetic chef” will prepare an example meal in between sessions, walking guests through the recipe, ingredient selection, cooking tips and more.

**Location:** Hyatt Regency Orlando, Plaza International Ballroom D-G  
**Contact:** Robert Zorzi/E-mail: rzorzi@medscape.net

**MONDAY, JUNE 25, 2018:**

**6:45 p.m.–8:45 p.m.**

**Treating Diabetic Dyslipidemia: A Deep Dive into PCSK9 Inhibitors**

**Provided by Vindico Medical Education**

**Supported by an educational grant from Amgen, Inc.**

(6:45 p.m.–7:15 p.m.-Registration and Dinner/7:15 p.m.–8:45 p.m.-CME-certified Activity)

This educational activity will review the latest data regarding the management of dyslipidemia in patients with diabetes, as well as assess the newly released data regarding the safety, efficacy, and reduction in adverse cardiovascular outcomes with PCSK9 inhibitor therapy.

**Location:** Hyatt Regency Orlando, Plaza International Ballroom D-G  
**Contact:** Kristin Riday/E-mail: kriday@vindicomeded.com

**6:45 p.m.–9:45 p.m.**

**Medical Crossfire®: Advancing the Role of the SGLT2 Inhibitors in the T2D Treatment Paradigm**

**Sponsored by Physicians’ Education Resource (PER)**

**Supported by an educational grant from Janssen Pharmaceuticals, Inc.**

Through a Medical Crossfire®, faculty will provide expert interpretation and guidance on the impact and clinical application of recent cardiovascular outcomes trials for achieving glycemic control with SGLT2 inhibitors. Participant interactivity and Infograph-ed™ will be included to better understand and incorporate cardiometabolic risk-reduction strategies into practice.

**Location:** Hyatt Regency Orlando, Regency Ballroom O-R  
**Contact:** Katie Pierson/E-mail: KPierson@permedical.com

Updated 5/29/18
Improving Obesity Care: A Practical Guide to Engaging and Treating Patients

*Sponsored by* The Endocrine Society
*Supported by an educational grant from* Novo Nordisk

(6:45 p.m. – 7:15 p.m. – Dinner/ 7:15 p.m. – 9:45 p.m. – Program)

This interactive CME activity will focus on patient-centered strategies to long-term weight loss maintenance, barriers to initiating and maintaining care, and evidence-based guidelines in selecting pharmacotherapy to treat patients. The symposium is accredited for 2.5 AMA PRA Category 1 Credits™ and 2.5 ABIM MOC Points and is chaired by Dr. Robert Kushner.

**Location:** Hyatt Regency Orlando, Regency Ballroom S-V
**Contact:** Cassandre Destin/E-mail: cdestin@endocrine.org